APA

Ganesan S., Alex A. A., Chendamarai E., Balasundaram N., Palani H. K., David S., Kulkarni U., Aiyaz M., Mugasimangalam R., Korula A., Abraham A., Srivastava A., Padua R. A., Chomienne C., George B., Balasubramanian P. & Mathews V. (20170814). Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. : Leukemia.

Chicago

Ganesan S, Alex A A, Chendamarai E, Balasundaram N, Palani H K, David S, Kulkarni U, Aiyaz M, Mugasimangalam R, Korula A, Abraham A, Srivastava A, Padua R A, Chomienne C, George B, Balasubramanian P and Mathews V. 20170814. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. : Leukemia.

Harvard

Ganesan S., Alex A. A., Chendamarai E., Balasundaram N., Palani H. K., David S., Kulkarni U., Aiyaz M., Mugasimangalam R., Korula A., Abraham A., Srivastava A., Padua R. A., Chomienne C., George B., Balasubramanian P. and Mathews V. (20170814). Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. : Leukemia.

MLA

Ganesan S, Alex A A, Chendamarai E, Balasundaram N, Palani H K, David S, Kulkarni U, Aiyaz M, Mugasimangalam R, Korula A, Abraham A, Srivastava A, Padua R A, Chomienne C, George B, Balasubramanian P and Mathews V. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. : Leukemia. 20170814.